Use of epidemiological analyses in Clinical Practice Guideline development focused on the diabetic patients treated with insulin.

Q3 Medicine
Miloslav Klugar, Jitka Klugarová, Andrea Pokorná, Klára Benešová, Jiří Jarkovský, Dana Dolanová, Jan Mužík, Radim Líčeník, Martin Prázný, Petra Búřilová, Martin Hunčovský, Tomáš Nečas, Zuzana Kelnarová, Ladislav Dušek
{"title":"Use of epidemiological analyses in Clinical Practice Guideline development focused on the diabetic patients treated with insulin.","authors":"Miloslav Klugar,&nbsp;Jitka Klugarová,&nbsp;Andrea Pokorná,&nbsp;Klára Benešová,&nbsp;Jiří Jarkovský,&nbsp;Dana Dolanová,&nbsp;Jan Mužík,&nbsp;Radim Líčeník,&nbsp;Martin Prázný,&nbsp;Petra Búřilová,&nbsp;Martin Hunčovský,&nbsp;Tomáš Nečas,&nbsp;Zuzana Kelnarová,&nbsp;Ladislav Dušek","doi":"10.1097/XEB.0000000000000188","DOIUrl":null,"url":null,"abstract":"<p><p>The prevalence of diabetes is on the rise worldwide especially in developed countries. The aim of glucose management in all types of diabetes is to minimize chronic and acute complications associated with diabetes. All patients with type 1 diabetes mellitus (T1DM) require insulin. Main areas of technology advances in diabetes are continuous subcutaneous insulin infusion (CSII) and also continuous glucose monitoring systems for the management of patients with both types of diabetes. It is very important to analyse the epidemiological situation within each country before and during the clinical practice guidelines (CPGs) development and implementation. The analyses will allow us to monitor the effect of the CPG after its implementation.The aim of this short communication is to analyse the epidemiology of prevalence and incidence of diabetes mellitus and use of CSII to inform development of CPGs in the Czech Republic.The analysis is developed based on the data managed by Institute of Health Information and Statistics of the Czech Republic. We used the National Register of Reimbursed Health Services 2015-2017 as primary source, and the annual report type A (Ministry of Health) 1-01: for Diabetology (A MH 004) 2007-2017 was used as validation source. The presented data are related to the year 2016 because we were able to validate them based on the data from 2015 to 2017 for this cohort of patients.The number of patients with T1DM is increasing in the Czech Republic with no significant sex difference. Life expectancy is about 11 years lower in the T1DM population. The majority of the patients are in older age; however, these are not treated with CSII compared with the younger population. From 61 533 patients with T1DM, 81% were reported with acute and chronic complications in 2016. Only 5011 of these patients were reported as using CSII.</p>","PeriodicalId":55996,"journal":{"name":"International Journal of Evidence-Based Healthcare","volume":"17 Suppl 1 ","pages":"S48-S52"},"PeriodicalIF":0.0000,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XEB.0000000000000188","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Evidence-Based Healthcare","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/XEB.0000000000000188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

The prevalence of diabetes is on the rise worldwide especially in developed countries. The aim of glucose management in all types of diabetes is to minimize chronic and acute complications associated with diabetes. All patients with type 1 diabetes mellitus (T1DM) require insulin. Main areas of technology advances in diabetes are continuous subcutaneous insulin infusion (CSII) and also continuous glucose monitoring systems for the management of patients with both types of diabetes. It is very important to analyse the epidemiological situation within each country before and during the clinical practice guidelines (CPGs) development and implementation. The analyses will allow us to monitor the effect of the CPG after its implementation.The aim of this short communication is to analyse the epidemiology of prevalence and incidence of diabetes mellitus and use of CSII to inform development of CPGs in the Czech Republic.The analysis is developed based on the data managed by Institute of Health Information and Statistics of the Czech Republic. We used the National Register of Reimbursed Health Services 2015-2017 as primary source, and the annual report type A (Ministry of Health) 1-01: for Diabetology (A MH 004) 2007-2017 was used as validation source. The presented data are related to the year 2016 because we were able to validate them based on the data from 2015 to 2017 for this cohort of patients.The number of patients with T1DM is increasing in the Czech Republic with no significant sex difference. Life expectancy is about 11 years lower in the T1DM population. The majority of the patients are in older age; however, these are not treated with CSII compared with the younger population. From 61 533 patients with T1DM, 81% were reported with acute and chronic complications in 2016. Only 5011 of these patients were reported as using CSII.

流行病学分析在临床实践指南制定中的应用,重点关注胰岛素治疗的糖尿病患者。
糖尿病的患病率在世界范围内呈上升趋势,特别是在发达国家。在所有类型的糖尿病中,血糖管理的目的是尽量减少与糖尿病相关的慢性和急性并发症。所有1型糖尿病(T1DM)患者都需要胰岛素。糖尿病技术进步的主要领域是连续皮下胰岛素输注(CSII)和连续血糖监测系统,用于两种糖尿病患者的管理。在制定和实施临床实践指南之前和期间分析每个国家内部的流行病学情况非常重要。通过这些分析,我们可以在实施CPG后监测其效果。本简短交流的目的是分析糖尿病流行病学和发病率,以及CSII的使用情况,为捷克共和国CPGs的制定提供信息。该分析是根据捷克共和国卫生信息和统计研究所管理的数据编制的。我们使用2015-2017年国家报销卫生服务登记册作为主要来源,并使用2007-2017年年度报告A(卫生部)1-01:糖尿病(A MH 004)作为验证来源。所呈现的数据与2016年有关,因为我们能够根据该队列患者2015年至2017年的数据对其进行验证。捷克共和国T1DM患者数量呈增加趋势,性别差异不显著。T1DM人群的预期寿命要低11年左右。患者以老年患者居多;然而,与年轻人群相比,这些人没有接受CSII治疗。在2016年61533例T1DM患者中,81%报告有急性和慢性并发症。这些患者中只有5011例报告使用CSII。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
0.00%
发文量
39
期刊介绍: ​​The International Journal of Evidence-Based Healthcare is the official journal of the Joanna Briggs Institute. It is a fully refereed journal that publishes manuscripts relating to evidence-based medicine and evidence-based practice. It publishes papers containing reliable evidence to assist health professionals in their evaluation and decision-making, and to inform health professionals, students and researchers of outcomes, debates and developments in evidence-based medicine and healthcare. ​ The journal provides a unique home for publication of systematic reviews (quantitative, qualitative, mixed methods, economic, scoping and prevalence) and implementation projects including the synthesis, transfer and utilisation of evidence in clinical practice. Original scholarly work relating to the synthesis (translation science), transfer (distribution) and utilization (implementation science and evaluation) of evidence to inform multidisciplinary healthcare practice is considered for publication. The journal also publishes original scholarly commentary pieces relating to the generation and synthesis of evidence for practice and quality improvement, the use and evaluation of evidence in practice, and the process of conducting systematic reviews (methodology) which covers quantitative, qualitative, mixed methods, economic, scoping and prevalence methods. In addition, the journal’s content includes implementation projects including the transfer and utilisation of evidence in clinical practice as well as providing a forum for the debate of issues surrounding evidence-based healthcare.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信